如何治疗复发性多发性骨髓瘤
本文综述复发性多发性骨髓瘤的治疗策略。来那度胺耐药是挽救治疗选择的关键因素,达雷妥尤单抗一线使用增多使耐药后复发成为常见挑战。三药方案是复发疾病的标准治疗,加入新机制药物可改善结局并克服类别耐药。
要点
- 来那度胺耐药是复发性骨髓瘤选择挽救治疗的最关键因素。
- 三药方案是管理复发性骨髓瘤的标准方法。
- 加入新机制药物可改善结局并克服类别耐药。
核心结论
- 尽管有新药和细胞治疗等新选择,对一线主要药物类别的耐药仍是复发时选择治疗的最关键因素。
- 来那度胺持续治疗广泛用于一线,来那度胺耐药已成为挽救治疗选择的关键因素。
- 达雷妥尤单抗越来越多用于一线,不久后在使用达雷妥尤单抗期间复发的患者将成为常见挑战。
- 三药方案是管理复发性疾病的标准方法,加入新机制药物可改善结局并克服类别耐药。
- 生物学虽重要,但目前对治疗选择只能提供有限指导。
研究设计与样本
- 本文为关于复发性多发性骨髓瘤治疗的综述。
主要发现
- 多发性骨髓瘤对多数患者仍不可治愈,初始缓解后会出现需要治疗的复发。
- 许多患者会经历多次缓解和复发,直至对所有可用治疗产生耐药。
- 新药类的引入使骨髓瘤治疗发生巨大变化,复发性或难治性疾病有了新选择,包括作用机制不同的新药类和细胞治疗。
临床怎么用
- 复发性疾病采用三药方案管理,可加入新机制药物以改善结局并克服类别耐药。
局限性
- 生物学虽重要,但目前对治疗选择只能提供有限指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite recent advances, multiple myeloma remains an incurable disease for most patients, and initial remission will be followed by relapses requiring therapy. For many, there will be several remissions and relapses until resistance develops to all available therapies. With the introduction of several new agents, myeloma treatment has changed drastically, and there are new options for the management of relapsed or refractory disease, including new drug classes with distinct mechanisms of action and cellular therapies. However, resistance to major drug classes used in first-line remains the most critical factor for the choice of treatment at relapse. Continuous lenalidomide-based therapy is used extensively at first-line, and resistance to lenalidomide has become the key factor for the choice of salvage therapy. Daratumumab is increasingly used in first-line, and soon patients that relapse while on daratumumab will become a common challenge. Three-drug regimens are the standard approach to manage relapsed disease. Adding drugs with new mechanisms of activity can improve outcomes and overcomes class resistance, but, until now, while biology is important, it can offer only limited guidance for the choice of therapy.
引用
- Kastritis E, Terpos E, Dimopoulos MA, et al. How I treat relapsed multiple myeloma. Blood. 2022. PMID: 35007326. doi:10.1182/blood.2020008734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。